| Symbol | VRAX |
|---|---|
| Name | VIRAX BIOLABS GROUP LTD |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Address | BIOCITY GLASGOW, LANARKSHIRE, X0 ML1 5UH |
| Telephone | 44 020 7788 7414 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001885827 |
| Description | None |
New Form F-3 - Virax Biolabs Group Ltd <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0001193125-26-316130 <b>Size:</b> 675 KB
Read moreVirax Biolabs CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Read moreVirax Biolabs CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreVirax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Read moreVirax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Read moreVirax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Read more